Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
https://www.zacks.com/stock/news/2274187/eli-lilly-lly-settles-with-spa-selling-mounjaro-zepbound-copies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2274187
May 15, 2024 - Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
0
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
https://www.fool.com/investing/2024/05/12/amgen-is-working-on-a-wegovy-competitor-what-it-me/?source=iedfolrf0000001
May 12, 2024 - The biotech's pipeline extends far beyond this exciting weight-loss product.
0
Here's What Key Metrics Tell Us About Amgen (AMGN) Q1 Earnings
https://www.zacks.com/stock/news/2267471/here-s-what-key-metrics-tell-us-about-amgen-amgn-q1-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2267471
May 02, 2024 - The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
https://www.zacks.com/stock/news/2265330/will-these-5-drug-biotech-stocks-beat-q1-earnings-forecast?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2265330
Apr 30, 2024 - Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
0
What's in the Cards for Amgen (AMGN) This Earnings Season?
https://www.zacks.com/stock/news/2264395/what-s-in-the-cards-for-amgen-amgn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2264395
Apr 29, 2024 - Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
0
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
https://www.zacks.com/stock/news/2262673/astrazeneca-azn-q1-earnings-sales-beat-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2262673
Apr 25, 2024 - AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
0
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
https://www.zacks.com/stock/news/2257263/amgen-amgn-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2257263
Apr 17, 2024 - Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
0
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
https://www.zacks.com/stock/news/2248594/why-amgen-amgn-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2248594
Apr 01, 2024 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
Wall Street Awaits Consumer Confidence Data
https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data?cid=CS-ZC-FT-economic_highlights-2246106
Mar 26, 2024 - Wall Street Awaits Consumer Confidence Data
0
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
https://www.zacks.com/stock/news/2244204/acelyrin-slrn-up-on-data-from-thyroid-eye-disease-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244204
Mar 21, 2024 - ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.
0